Skip to content

Disc Medicine IRON Change in Other Assets

Change in Other Assets at other companies

Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$1.92M+102%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
$2.46M+15.6%
Beam Therapeutics logo
Beam TherapeuticsBEAM
$31.86M+65,122%
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
$6.38M+282%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$18.85M+3,770%
PTC Therapeutics logo
PTC TherapeuticsPTCT
-$1.18M-107%

Other financials

Income statement

See full
Operating income-$69.5M-74.0%
Net income-$63.5M-86.3%
EPS (diluted)-$1.65-61.8%

Balance sheet

See full
Cash & equivalents$88.9M-27.5%
Total debt$31.1M+1.4%
Total equity$688.4M+4.3%
Total assets$750.2M+5.8%

Cash flow

See full
Operating cash flow-$62.2M-50.4%
CapEx--100%
Free cash flow-$62.2M-47.4%

Valuation

See full
Market cap$2.69B+42.2%
Enterprise value$2.63B+46.7%

Returns & leverage

See full
Return on equity-35.8%+41.3pp
Debt / equity0.0×
Current ratio24×-13.6×

Where this comes from

Reported directly by Disc Medicine in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.

The official record: Disc Medicine’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Disc Medicine's change in other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Disc Medicine's change in other assets?
Disc Medicine (IRON) reported change in other assets of $4.55M in Q1 2026.
How has Disc Medicine's change in other assets changed year-over-year?
Disc Medicine's change in other assets decreased by 37.1% year-over-year, from $7.23M to $4.55M.
What is the long-term trend for Disc Medicine's change in other assets?
Over 2 years (2022 to 2025), Disc Medicine's change in other assets has grown at a 413.8% compound annual growth rate (CAGR), from -$352K to $9.29M.
What does change in other assets mean?
Change in miscellaneous assets affecting operating cash flow.